Edition:
United States

Achaogen Inc (AKAO.OQ)

AKAO.OQ on NASDAQ Stock Exchange Global Market

11.83USD
17 Nov 2017
Change (% chg)

$-0.12 (-1.00%)
Prev Close
$11.95
Open
$11.89
Day's High
$12.03
Day's Low
$11.68
Volume
237,101
Avg. Vol
222,381
52-wk High
$27.78
52-wk Low
$4.71

Latest Key Developments (Source: Significant Developments)

Achaogen reports Q3 loss per share $0.85
Wednesday, 8 Nov 2017 04:01pm EST 

Nov 8 (Reuters) - Achaogen Inc ::Achaogen reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.85.Q3 earnings per share view $-0.72 -- Thomson Reuters I/B/E/S.Achaogen - ‍unrestricted cash, cash equivalents and short-term investments totaled $199.4 million at Sept 30, 2017 compared to $145.9 million at Dec 31, 2016​.  Full Article

Achaogen submits Plazomicin new drug application to FDA
Thursday, 26 Oct 2017 08:01am EDT 

Oct 26 (Reuters) - Achaogen Inc :Achaogen submits Plazomicin new drug application (NDA) to the U.S. FDA for treatment of complicated urinary tract infections and bloodstream infections.Achaogen Inc - co also intends to submit an application for registration of Plazomicin​ in European Union in 2018.  Full Article

Achaogen awarded up to $18 million contract by BARDA
Thursday, 28 Sep 2017 08:01am EDT 

Sept 28 (Reuters) - Achaogen Inc ::Achaogen awarded up to $18 million contract by BARDA to support development of orally-administered antibacterial candidate C-Scape.Achaogen-BARDA contract includes 9 month base period with committed funding of $12 million,option periods,if exercised,to raise value of award to $18 million​.Achaogen Inc - ‍advance C-Scape through a streamlined development approach with an aim of initiating a pivotal Phase 3 trial next year​.  Full Article

Achaogen reports Q2 loss per share $0.78
Thursday, 3 Aug 2017 04:01pm EDT 

Aug 3 (Reuters) - Achaogen Inc :Achaogen reports second quarter 2017 financial results and provides corporate update.Q2 loss per share $0.78.Q2 earnings per share view $-0.62 -- Thomson Reuters I/B/E/S.Qtrly ‍contract revenue $1.27 million versus $9.14 million.  Full Article

Point72 Asset Management reports 5.5 pct passive stake in Achaogen
Wednesday, 26 Jul 2017 05:10pm EDT 

July 26 (Reuters) - Achaogen Inc ::Point72 Asset Management Lp reports 5.5 percent passive stake in Achaogen Inc as of july 25 - sec filing.  Full Article

Achaogen announces pricing of public offering of common stock
Thursday, 25 May 2017 08:00am EDT 

May 25 (Reuters) - Achaogen Inc :Achaogen announces pricing of public offering of common stock.Says public offering of 5.00 million common shares priced at $22.50per share.  Full Article

Achagaon says FDA grants its antibiotic Plazomicin "breakthrough therapy" status
Tuesday, 23 May 2017 04:07pm EDT 

May 23 (Reuters) - Achaogen Inc :Plazomicin granted fda breakthrough therapy designation.Co intends to include care trial data, along with data from epic trial, in an nda submission in second half of 2017.  Full Article

Achaogen offers up to 5 mln shares in public offering
Tuesday, 23 May 2017 04:03pm EDT 

May 23 (Reuters) - Achaogen Inc :Achaogen announces proposed public offering of common stock.Achaogen inc- commenced an underwritten public offering of up to 5 million shares of its common stock.Achaogen - expects to use net proceeds from offering to fund its ongoing development and preparation for potential commercialization of plazomicin.  Full Article

Achaogen files for potential mixed shelf offering
Monday, 8 May 2017 05:31pm EDT 

May 8 (Reuters) - Achaogen Inc ::Files for potential mixed shelf offering; size not disclosed - SEC filing.  Full Article

Achaogen reports Q1 loss per share $0.93
Monday, 8 May 2017 04:01pm EDT 

May 8 (Reuters) - Achaogen Inc :Achaogen reports first quarter 2017 financial results and provides corporate update.Q1 loss per share $0.93.Q1 earnings per share view $-0.54 -- Thomson Reuters I/B/E/S.Achaogen Inc - plazomicin registration activities on track; nda submission planned for second half of 2017.Achaogen Inc - plan to initiate a phase 1 c-scape clinical trial program in Q2 of 2017.Achaogen Inc - contract revenue totaled $7.5 million for Q1 of 2017 compared to $5.8 million for same period of 2016..  Full Article

BRIEF-Achaogen reports Q3 loss per share $0.85

* Achaogen reports third quarter 2017 financial results and provides corporate update